RxDoctor Payments Data

William Freeman, MD

Dermatology · Warner Robins, GANPI 1649267667

Payments from drug & device makers

$8,729in general payments, 2019–2025

Across 125 payments — averaging $69.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$3K
  • Senseonics, Incorporated$2K
  • AbbVie$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Johnson & Johnson$579
  • Lilly USA, LLC$253
  • plus $1K from 12 others

What the payments were for

  • Speaking & faculty fees$3,61641%
  • Food & beverage$4,85656%
  • Education$2573%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,729 in reported general payments places this provider in the 70th percentile of 345 dermatology providers in Georgia.

See all dermatology providers in Georgia

Medicare billing

Part B allowed, 2024
$2,745,465
Medicare patients
2,865
Services billed
31,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab51$273,361
OtezlaApremilast26$164,725
Cosentyx Sensoready (2 Pens)Secukinumab21$151,763
Dupixent SyringeDupilumab33$143,442
Ketoconazole220$4,180
Metronidazole35$3,758
Clobetasol Propionate36$2,795
Hydrocortisone139$1,722
Triamcinolone Acetonide207$1,708
Fluorouracil23$1,607
Clindamycin Phosphate54$1,330
Fluocinonide27$1,248
Tacrolimus11$1,115
Mometasone Furoate59$1,081
Imiquimod14$877

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$23$164,72526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 345 dermatology providers in Georgia.

Other dermatology in Warner Robins

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →